Lumipulse® G PIVKA-II

Getting a better view on liver cancer

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of protein induced vitamin K absence or antagonist-II (PIVKA-II) in serum. The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.

Lumipulse® G PIVKA-II Immunoreaction Cartridges:

  • Art. no. 233184 (3 x 14 Tests - CE) - This product is not available in the USA and in Canada.

Lumipulse® G PIVKA-II Calibrators Set:

  • Art. no. 233191 (2 x 3 x 1.5 ml - CE) - This product is not available in the USA and in Canada.   

 

  • Allows stratification of patients on transplant waiting list.

  • Predicts recurrence of HCC.

  • Complementary to AFP for improved detection of (early) HCC. 

 

Product benefits

Complete Solution

  • CE-marked
  • Only assay available on an automated platform (LUMIPULSE G1200)
  • Oncology menu available for routine, specialized and unique markers
  • Chemiluminescent assay
  • Calibrators and controls available

Different clinical applications

  • Monitoring: Correlation with microvascular invasion, recurrence and tumor size
  • Diagnosis: Complementary to AFP for the improved detection of HCC

 

Assay technology

CLEIA - ChemiLuminescent Enzyme Immunoassay 

 

Test principle: Two-Step sandwich assay 

 

Clinical background  

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with a high rate of mortality and an increasing incidence. The most common causes of HCC are either a viral hepatitis infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis). The starting point in the diagnostic surveillance of at risk patients is ultrasound. In a second stage this can be completed with the measurement of a tumor marker called α-fetoprotein (AFP). Since ultrasound has a poor performance in cirrhotic patients and is also operator dependent, further characterization by CT or MRI is often required. As it is important to detect HCC at an early stage when the disease is still curable, biomarkers can complete the diagnosis obtained with ultrasound before moving on to the more expensive MRI. Biomarkers can also be used to better stratify patients on the liver transplant waiting list. Additionally, the risk of recurrence of HCC after transplantation can be assessed by monitoring patients with biomarkers.

 

See the LUMIPULSE G1200 working in this video:

Welcome to Fujirebio

Please indicate from which location you are connecting:

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.

More than 50 years of pioneering expertise in IVD

Image

We are a global leader in the field of high quality in vitro diagnostics (IVD) testing. We have more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Our IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.

CLOSE

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Looking for additional resources?

Create your free eServices account and get access to all our extra documentation (certificates, data sheets, ...), event dates where our products are presented, FAQs, ...

  • Find & download CoA, SDS and CE declarations of conformity
  • Unlimited access to our free eLearning videos
  • See all event dates where our products are presented

Already have an account? Log in here